Assetmark, Inc Viking Therapeutics, Inc. Transaction History
Assetmark, Inc
- $45.6 Billion
- Q3 2025
A detailed history of Assetmark, Inc transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Assetmark, Inc holds 12,397 shares of VKTX stock, worth $493,400. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12,397
Previous 12,917
4.03%
Holding current value
$493,400
Previous $342,000
7.6%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding VKTX
# of Institutions
435Shares Held
66.6MCall Options Held
7.21MPut Options Held
3.87M-
Vanguard Group Inc Valley Forge, PA10MShares$398 Million0.0% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$240 Million0.01% of portfolio
-
State Street Corp Boston, MA4.51MShares$180 Million0.0% of portfolio
-
Morgan Stanley New York, NY3.73MShares$148 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.58MShares$103 Million0.0% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $3.05B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...